BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001;33:62-5. [PMID: 11124821 DOI: 10.1053/jhep.2001.21041] [Cited by in Crossref: 280] [Cited by in F6Publishing: 252] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Hoofnagle JH. Hepatocellular carcinoma: summary and recommendations. Gastroenterology 2004;127:S319-23. [PMID: 15508100 DOI: 10.1053/j.gastro.2004.09.047] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.0] [Reference Citation Analysis]
2 Jia Z, Wang L, Liu C, Yu Z, Chai L, Zhao M. Evaluation of α-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn). 2014;18:192-196. [PMID: 25520580 DOI: 10.5114/wo.2014.43157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
3 Njei B, McCarty TR, Birk JW. Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol. 2016;31:1141-1146. [PMID: 26749521 DOI: 10.1111/jgh.13289] [Cited by in Crossref: 125] [Cited by in F6Publishing: 114] [Article Influence: 25.0] [Reference Citation Analysis]
4 Lee QN, Akra GA, Kigotho AG, Ahadi MS. Ruptured hepatocellular carcinoma disguising as heterotopic pregnancy. BMJ Case Rep 2018;2018:bcr-2017-222514. [PMID: 29487098 DOI: 10.1136/bcr-2017-222514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Nguyen VT, Amin J, Law MG, Dore GJ. Predictors and survival in hepatitis B-related hepatocellular carcinoma in New South Wales, Australia. J Gastroenterol Hepatol. 2009;24:436-442. [PMID: 19175834 DOI: 10.1111/j.1440-1746.2008.05577.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hernández-Guerra M, Hernández-Camba A, Turnes J, Ramos LM, Arranz L, Mera J, Crespo J, Quintero E. Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival. United European Gastroenterol J 2015;3:284-93. [PMID: 26279838 DOI: 10.1177/2050640615575971] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Blazeby JM, Currie E, Zee BC, Chie WC, Poon RT, Garden OJ. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer. 2004;40:2439-2444. [PMID: 15519517 DOI: 10.1016/j.ejca.2004.06.033] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 3.1] [Reference Citation Analysis]
8 Moreno-Luna LE, Arrieta O, García-Leiva J, Martínez B, Torre A, Uribe M, León-Rodríguez E. Clinical and pathologic factors associated with survival in young adult patients with fibrolamellar hepatocarcinoma. BMC Cancer 2005;5:142. [PMID: 16259635 DOI: 10.1186/1471-2407-5-142] [Cited by in Crossref: 42] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
9 Huether A, Höpfner M, Sutter AP, Schuppan D, Scherübl H. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005;43:661-669. [PMID: 16023762 DOI: 10.1016/j.jhep.2005.02.040] [Cited by in Crossref: 99] [Cited by in F6Publishing: 101] [Article Influence: 5.8] [Reference Citation Analysis]
10 Iwaki K, Ohta M, Ishio T, Kai S, Iwashita Y, Shibata K, Himeno K, Seike M, Fujioka T, Kitano S. Metastasis of hepatocellular carcinoma to spleen and small intestine. J Hepatobiliary Pancreat Surg 2008;15:213-9. [PMID: 18392718 DOI: 10.1007/s00534-007-1230-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
11 Hench LL. Glass and Glass-Ceramic Technologies to Transform the World. Int J Appl Glass Sci 2011;2:162-76. [DOI: 10.1111/j.2041-1294.2011.00056.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
12 El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R, McGlynn KA. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006;44:158-166. [PMID: 16290309 DOI: 10.1016/j.jhep.2005.10.002] [Cited by in Crossref: 168] [Cited by in F6Publishing: 150] [Article Influence: 9.9] [Reference Citation Analysis]
13 Kositamongkol P, Sanphasitvong V, Sirivatanauksorn Y, Pongpaibul A, Limsrichamrern S, Mahawithitwong P, Asavakarn S, Tovikkai C, Dumronggittigule W. Outcome of Liver Transplantation in Hepatocellular Carcinoma Patients at Siriraj Hospital. Transplant Proc 2017;49:1114-7. [PMID: 28583538 DOI: 10.1016/j.transproceed.2017.03.047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
14 Mondal G, Saroha A, Bose PP, Chatterjee BP. Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients. Glycoconj J 2016;33:209-18. [PMID: 27034286 DOI: 10.1007/s10719-016-9658-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
15 Chen PH, Lin YC, Tu HP, Chiang SL, Ko AM, Hsu CL, Chang YF, Ko YC. Important prognostic factors for the long-term survival of subjects with primary liver cancer in Taiwan: a hyperendemic area. Eur J Cancer 2007;43:1076-84. [PMID: 17329095 DOI: 10.1016/j.ejca.2007.01.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
16 Okuda K. Natural history of hepatocellular carcinoma including fibrolamellar and hepato-cholangiocarcinoma variants. J Gastroenterol Hepatol. 2002;17:401-405. [PMID: 11982719 DOI: 10.1046/j.1440-1746.2002.02734.x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 63] [Article Influence: 3.7] [Reference Citation Analysis]
17 Fecht WJ Jr, Befeler AS. Hepatocellular carcinoma: updates in primary prevention. Curr Gastroenterol Rep 2004;6:37-43. [PMID: 14720452 DOI: 10.1007/s11894-004-0024-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
18 Chen M, Huang JD, Hu L, Zheng BJ, Chen L, Tsang SL, Guan XY. Transgenic CHD1L expression in mouse induces spontaneous tumors. PLoS One. 2009;4:e6727. [PMID: 19701453 DOI: 10.1371/journal.pone.0006727] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
19 Yang W, Lu Y, Xu Y, Xu L, Zheng W, Wu Y, Li L, Shen P. Estrogen represses hepatocellular carcinoma (HCC) growth via inhibiting alternative activation of tumor-associated macrophages (TAMs). J Biol Chem. 2012;287:40140-40149. [PMID: 22908233 DOI: 10.1074/jbc.M112.348763] [Cited by in Crossref: 64] [Cited by in F6Publishing: 42] [Article Influence: 6.4] [Reference Citation Analysis]
20 Bruno S, Savojardo D, Almasio PL, Mondelli MU. Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med 2011;3:21-8. [PMID: 24367218 DOI: 10.2147/HMER.S16991] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
21 Wu C, Chan T, Changchien C, Yang C. Parity, age at first birth, and risk of death from liver cancer: Evidence from a cohort in Taiwan: Reproductive factors and liver cancer. Journal of Gastroenterology and Hepatology 2011;26:334-9. [DOI: 10.1111/j.1440-1746.2010.06365.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
22 Nagoshi S. Sex- or gender-specific medicine in hepatology. Hepatol Res. 2008;38:219-224. [PMID: 18047583 DOI: 10.1111/j.1872-034x.2007.00301.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
23 Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, Block TM, Mehta AS. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1914-1921. [PMID: 19454616 DOI: 10.1158/1055-9965.epi-08-0980] [Cited by in Crossref: 112] [Cited by in F6Publishing: 68] [Article Influence: 8.6] [Reference Citation Analysis]
24 Grindel BJ, Rohe B, Safford SE, Bennett JJ, Farach-Carson MC. Tumor necrosis factor-α treatment of HepG2 cells mobilizes a cytoplasmic pool of ERp57/1,25D₃-MARRS to the nucleus. J Cell Biochem 2011;112:2606-15. [PMID: 21598303 DOI: 10.1002/jcb.23187] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
25 Mondal G, Chatterjee U, Chawla YK, Chatterjee BP. Alterations of glycan branching and differential expression of sialic acid on alpha fetoprotein among hepatitis patients. Glycoconj J. 2011;28:1-9. [PMID: 21161373 DOI: 10.1007/s10719-010-9316-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
26 Nakamura S, Nouso K, Noguchi Y, Higashi T, Ono T, Jungbluth A, Chen YT, Old LJ, Nakayama E, Shiratori Y. Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 2006;21:1281-5. [PMID: 16872310 DOI: 10.1111/j.1440-1746.2006.04271.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
27 Hassan MM, Botrus G, Abdel-Wahab R, Wolff RA, Li D, Tweardy D, Phan AT, Hawk E, Javle M, Lee JS, Torres HA, Rashid A, Lenzi R, Hassabo HM, Abaza Y, Shalaby AS, Lacin S, Morris J, Patt YZ, Amos CI, Khaderi SA, Goss JA, Jalal PK, Kaseb AO. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2017;15:1791-9. [PMID: 28579181 DOI: 10.1016/j.cgh.2017.05.036] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
28 Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24. [PMID: 11870363 DOI: 10.1053/jhep.2002.32089] [Cited by in Crossref: 821] [Cited by in F6Publishing: 769] [Article Influence: 41.1] [Reference Citation Analysis]
29 Tilocca A. Realistic Models of Bioactive Glass Radioisotope Vectors in Practical Conditions: Structural Effects of Ion Exchange. J Phys Chem C 2015;119:27442-8. [DOI: 10.1021/acs.jpcc.5b07804] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
30 Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JN, de Man RA, Pan Q, Sleijfer S, Bruno MJ, Kwekkeboom J. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.Br J Cancer. 2015;112:1911-1920. [PMID: 26057582 DOI: 10.1038/bjc.2015.92] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
31 Waziry R, Gomaa A, Waked I, Dore GJ. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab J Gastroenterol 2018;19:26-32. [PMID: 29506913 DOI: 10.1016/j.ajg.2018.02.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
32 Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R; EpaHCC Group. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncol 2013;9:283-94. [PMID: 23414477 DOI: 10.2217/fon.12.183] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 4.6] [Reference Citation Analysis]
33 Liu JH, Chen PW, Asch SM, Busuttil RW, Ko CY. Surgery for Hepatocellular Carcinoma: Does It Improve Survival? Ann Surg Oncol 2004;11:298-303. [DOI: 10.1245/aso.2004.03.042] [Cited by in Crossref: 64] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
34 Huang MA, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2002;18:345-50. [DOI: 10.1097/00001574-200205000-00008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
35 Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16. [PMID: 15795889 DOI: 10.1002/hep.20636] [Cited by in Crossref: 465] [Cited by in F6Publishing: 416] [Article Influence: 27.4] [Reference Citation Analysis]
36 Allen AM, Hay JE. Review article: the management of cirrhosis in women. Aliment Pharmacol Ther 2014;40:1146-54. [PMID: 25263269 DOI: 10.1111/apt.12974] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
37 El-serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatology Research 2007;37:S88-94. [DOI: 10.1111/j.1872-034x.2007.00168.x] [Cited by in Crossref: 215] [Cited by in F6Publishing: 108] [Article Influence: 14.3] [Reference Citation Analysis]
38 Wang M, Mehta A, Block TM, Marrero J, Di Bisceglie AM, Devarajan K. A comparison of statistical methods for the detection of hepatocellular carcinoma based on serum biomarkers and clinical variables. BMC Med Genomics. 2013;6 Suppl 3:S9. [PMID: 24564861 DOI: 10.1186/1755-8794-6-s3-s9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
39 Liao XF, Yi JL, Li XR, Deng W, Yang ZF, Tian G. Angiogenesis in rabbit hepatic tumor after transcatheter arterial embolization. World J Gastroenterol 2004; 10(13): 1885-1889 [PMID: 15222029 DOI: 10.3748/wjg.v10.i13.1885] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
40 Sandow T, Devun D, Gulotta P, Bohorquez H, Kirsch D. Elevated Lung Shunt Fraction as a Prognostic Indicator for Disease Progression and Metastasis in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2016;27:804-11. [DOI: 10.1016/j.jvir.2016.01.129] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, Goin K, Van Buskirk M, Thurston K. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16:195-203. [PMID: 15713920 DOI: 10.1097/01.rvi.0000142602.79459.90] [Cited by in Crossref: 87] [Cited by in F6Publishing: 19] [Article Influence: 5.1] [Reference Citation Analysis]
42 Hadush Tesfay A, Chou YJ, Tan CY, Fufa Bakare F, Tsou NT, Huang EW, Shih SJ. Control of Dopant Distribution in Yttrium-Doped Bioactive Glass for Selective Internal Radiotherapy Applications Using Spray Pyrolysis. Materials (Basel) 2019;12:E986. [PMID: 30934617 DOI: 10.3390/ma12060986] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Mao WL, Shi XP, Lou YF, Ye B, Lu YQ. The association between circulating oestradiol levels and severity of liver disease in males with hepatitis B virus infection. Liver Int. 2013;33:1211-1217. [PMID: 23551989 DOI: 10.1111/liv.12160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
44 Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther. 2004;19:1159-1172. [PMID: 15153169 DOI: 10.1111/j.1365-2036.2004.01963.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 103] [Article Influence: 7.0] [Reference Citation Analysis]
45 Zhang YC, Wang XP, Zhang LY, Song AL, Kou ZM, Li XS. Effect of blocking IGF-I receptor on growth of human hepatocellular carcinoma cells. World J Gastroenterol 2006; 12(25): 3977-3982 [PMID: 16810743 DOI: 10.3748/wjg.v12.i25.3977] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
46 O'Brien TR, Kirk G, Zhang M. Hepatocellular carcinoma: paradigm of preventive oncology. Cancer J. 2004;10:67-73. [PMID: 15130266 DOI: 10.1097/00130404-200403000-00002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
47 El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35:S72-S78. [PMID: 12394209 DOI: 10.1097/00004836-200211002-00002] [Cited by in Crossref: 440] [Cited by in F6Publishing: 421] [Article Influence: 23.2] [Reference Citation Analysis]
48 Capocaccia R, Sant M, Berrino F, Simonetti A, Santi V, Trevisani F; EUROCARE Working Group. Hepatocellular carcinoma: trends of incidence and survival in Europe and the United States at the end of the 20th century. Am J Gastroenterol 2007;102:1661-70; quiz 1660, 1671. [PMID: 17555459 DOI: 10.1111/j.1572-0241.2007.01337.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 6.7] [Reference Citation Analysis]
49 Morad WS, Basuni AA, Fouad T, El Latif HA, Salama M, El Aziz AA, El Satar YB, Zaki S, Shebl N, Raouf AM. The value of PIVKA-II and AFP-L3% in the diagnosis of hepatocellular carcinoma with normal and abnormal AFP levels: . Egyptian Liver Journal 2013;3:1-5. [DOI: 10.1097/01.elx.0000424246.18235.c5] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
50 Wong LL, Tsai N, Limm W, Wong L. Liver transplant for hepatocellular cancer: a treatment for the select few. Clin Transplant 2004;18:205-10. [PMID: 15016137 DOI: 10.1046/j.1399-0012.2003.00157.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
51 Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P'eng FK. Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg. 2005;92:348-355. [PMID: 15672423 DOI: 10.1002/bjs.4838] [Cited by in Crossref: 74] [Cited by in F6Publishing: 74] [Article Influence: 4.4] [Reference Citation Analysis]
52 Gao H, Lu Q, Liu X, Cong H, Zhao L, Wang H, Lin D. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009;100:782-785. [PMID: 19469021 DOI: 10.1111/j.1349-7006.2009.01086.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 136] [Article Influence: 10.6] [Reference Citation Analysis]
53 Höpfner M, Huether A, Sutter AP, Baradari V, Schuppan D, Scherübl H. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol. 2006;71:1435-1448. [PMID: 16530734 DOI: 10.1016/j.bcp.2006.02.006] [Cited by in Crossref: 84] [Cited by in F6Publishing: 82] [Article Influence: 5.3] [Reference Citation Analysis]
54 Mallat DB, El-Serag HB. Surveillance for hepatocellular carcinoma: does it work? Am J Gastroenterol 2002;97:2676-7. [PMID: 12385462 DOI: 10.1111/j.1572-0241.2002.07037.x] [Reference Citation Analysis]
55 Shoreibah MG, Bloomer JR, McGuire BM, Massoud OI. Surveillance for hepatocellular carcinoma: evidence, guidelines and utilization. Am J Med Sci. 2014;347:415-419. [PMID: 24759379 DOI: 10.1097/maj.0000000000000200] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
56 Gerolami R, Uch R, Faivre J, Garcia S, Hardwigsen J, Cardoso J, Mathieu S, Bagnis C, Brechot C, Mannoni P. Herpes simplex virus thymidine kinase-mediated suicide gene therapy for hepatocellular carcinoma using HIV-1-derived lentiviral vectors. J Hepatol. 2004;40:291-297. [PMID: 14739101 DOI: 10.1016/j.jhep.2003.10.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
57 Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, Li W, Bi J, Zhang LJ, Fu Q. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res. 2009;39:786-794. [PMID: 19473441 DOI: 10.1111/j.1872-034x.2009.00502.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 73] [Article Influence: 9.0] [Reference Citation Analysis]
58 Alkhalili E, Greenbaum A, Luo L, Rodriguez R, Munoz OE, O'Neill J, Nir I, Morris KT. Racial disparities in treatment and survival of hepatocellular carcinoma in native Americans and Hispanics. Am J Surg 2017;214:100-4. [PMID: 28624027 DOI: 10.1016/j.amjsurg.2016.09.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
59 Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35:S86-S91. [PMID: 12394211 DOI: 10.1097/00004836-200211002-00004] [Cited by in Crossref: 61] [Cited by in F6Publishing: 58] [Article Influence: 3.2] [Reference Citation Analysis]
60 Chinnaratha MA, Graham C, Fraser RJL, Woodman RJ, Wigg AJ. Rising incidence of hepatitis B-related hepatocellular carcinoma in South Australia: 1996-2010: Hepatitis B-related HCC in South Australia. Intern Med J 2016;46:902-8. [DOI: 10.1111/imj.13121] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
61 Lee NP, Cheung ST, Poon RT, Fan ST, Luk JM. Genomic and proteomic biomarkers for diagnosis and prognosis of hepatocellular carcinoma. Biomark Med 2007;1:273-84. [PMID: 20477402 DOI: 10.2217/17520363.1.2.273] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
62 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36:S74-83. [PMID: 12407579 DOI: 10.1053/jhep.2002.36807] [Cited by in Crossref: 37] [Cited by in F6Publishing: 135] [Article Influence: 1.9] [Reference Citation Analysis]
63 Ollivier I, Dauvois B, Guittet L, Boutreux S, Dupont B, Launoy G, Dao T. Survival improvement in Child–Pugh C cirrhotic patients with hepatocellular carcinoma diagnosed during 1990–2002. Gastroentérologie Clinique et Biologique 2010;34:288-96. [DOI: 10.1016/j.gcb.2010.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Ahmadzadehfar H, Sabet A, Wilhelm K, Biersack HJ, Risse J. Iodine-131-lipiodol therapy in hepatic tumours. Methods. 2011;55:246-252. [PMID: 21664971 DOI: 10.1016/j.ymeth.2011.05.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
65 Ramalingam R, Vaiyapuri M. Effects of umbelliferone on lipid peroxidation and antioxidant status in diethylnitrosamine-induced hepatocellular carcinoma. Journal of Acute Medicine 2013;3:73-82. [DOI: 10.1016/j.jacme.2013.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
66 Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Hayashi K, Honda T, Kitabatake S, Kuzuya T, Nonogaki K, Kasugai T, Shimizu J. Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan. Cancer. 2004;100:2415-2421. [PMID: 15160346 DOI: 10.1002/cncr.20289] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 1.8] [Reference Citation Analysis]
67 Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, Marrero JA. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47. [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x] [Cited by in Crossref: 496] [Cited by in F6Publishing: 420] [Article Influence: 38.2] [Reference Citation Analysis]
68 Wang Y, Lee AT, Ma JZ, Wang J, Ren J, Yang Y, Tantoso E, Li KB, Ooi LL, Tan P, Lee CG. Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem. 2008;283:13205-13215. [PMID: 18319255 DOI: 10.1074/jbc.m707629200] [Cited by in Crossref: 273] [Cited by in F6Publishing: 154] [Article Influence: 19.5] [Reference Citation Analysis]
69 Rui C, Li C, Xu W, Zhan Y, Li Y, Yang X. Involvement of Egr-1 in HGF-induced elevation of the human 5alpha-R1 gene in human hepatocellular carcinoma cells. Biochem J. 2008;411:379-386. [PMID: 18215136 DOI: 10.1042/BJ20071343] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
70 Vukotic R, Gramenzi A, Vitale G, Cursaro C, Serra C, Biselli M, Scuteri A, Andreone P, Bernardi M. Hepatocellular carcinoma appearance in patients with hepatitis C virus-related chronic liver disease 90 and 70 months after sustained virological response to interferon and ribavirin. Liver Int 2008;28:407-11. [PMID: 17900241 DOI: 10.1111/j.1478-3231.2007.01593.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
71 Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44:20-29. [PMID: 14681338 DOI: 10.1177/0091270003258669] [Cited by in Crossref: 339] [Cited by in F6Publishing: 333] [Article Influence: 18.8] [Reference Citation Analysis]
72 Nguyen MH, Whittemore AS, Garcia RT, Tawfeek SA, Ning J, Lam S, Wright TL, Keeffe EB. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004;2:820-4. [PMID: 15354283 DOI: 10.1016/s1542-3565(04)00353-2] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
73 Marrero JA, Pelletier S. Hepatocellular Carcinoma. Clinics in Liver Disease 2006;10:339-51. [DOI: 10.1016/j.cld.2006.05.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
74 Bhat M, Chaiteerakij R, Harmsen WS, Schleck CD, Yang JD, Giama NH, Therneau TM, Gores GJ, Roberts LR. Metformin does not improve survival in patients with hepatocellular carcinoma. World J Gastroenterol 2014; 20(42): 15750-15755 [PMID: 25400459 DOI: 10.3748/wjg.v20.i42.15750] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
75 Yang JD, Kim B, Sanderson SO, St Sauver JL, Yawn BP, Pedersen RA, Larson JJ, Therneau TM, Roberts LR, Kim WR. Hepatocellular carcinoma in olmsted county, Minnesota, 1976-2008. Mayo Clin Proc 2012;87:9-16. [PMID: 22212963 DOI: 10.1016/j.mayocp.2011.07.001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
76 Yin PH, Lee HC, Chau GY, Liu TY, Liu HC, Lui WY, Chi CW. Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett 2004;212:195-201. [PMID: 15341023 DOI: 10.1016/j.canlet.2004.04.032] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
77 Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) 2012;5:544-52. [PMID: 22467080 DOI: 10.1158/1940-6207.CAPR-11-0228] [Cited by in Crossref: 97] [Cited by in F6Publishing: 61] [Article Influence: 9.7] [Reference Citation Analysis]
78 Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, Trikha A, Sherman M, Sulkowski MS, Dieterich DT, Rigsby MO, Wright TL, Hernandez MD, Jain MK, Khatri GK, Sterling RK, Bonacini M, Martyn CA, Aytaman A, Llovet JM, Brown ST, Bini EJ. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study. Journal of Hepatology 2007;47:527-37. [DOI: 10.1016/j.jhep.2007.06.010] [Cited by in Crossref: 167] [Cited by in F6Publishing: 148] [Article Influence: 11.1] [Reference Citation Analysis]
79 Xiao Y, Liu G, Sun Y, Gao Y, Ouyang X, Chang C, Gong L, Yeh S. Targeting the estrogen receptor alpha (ERα)-mediated circ-SMG1.72/miR-141-3p/Gelsolin signaling to better suppress the HCC cell invasion. Oncogene 2020;39:2493-508. [PMID: 31996784 DOI: 10.1038/s41388-019-1150-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
80 Méndez-sánchez; N, Vásquez-fernández; F, Zamora-valdés; D, Uribe M. Sorafenib, a systemic therapy for hepatocellular carcinoma. Annals of Hepatology 2008;7:46-51. [DOI: 10.1016/s1665-2681(19)31886-1] [Cited by in Crossref: 23] [Article Influence: 1.6] [Reference Citation Analysis]
81 Makhdoumi P, Zarghi A, Daraei B, Karimi G. Evaluation of Cytotoxicity Effects of Chalcone Epoxide Analogues as a Selective COX-II Inhibitor in the Human Liver Carcinoma Cell Line. J Pharmacopuncture 2017;20:207-12. [PMID: 30087797 DOI: 10.3831/KPI.2017.20.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
82 Cuconati A, Mills C, Goddard C, Zhang X, Yu W, Guo H, Xu X, Block TM. Suppression of AKT anti-apoptotic signaling by a novel drug candidate results in growth arrest and apoptosis of hepatocellular carcinoma cells. PLoS One 2013;8:e54595. [PMID: 23355882 DOI: 10.1371/journal.pone.0054595] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
83 Wei Q, Guo P, Mu K, Zhang Y, Zhao W, Huai W, Qiu Y, Li T, Ma X, Liu Y, Chen X, Han L. Estrogen suppresses hepatocellular carcinoma cells through ERβ-mediated upregulation of the NLRP3 inflammasome. Lab Invest 2015;95:804-16. [DOI: 10.1038/labinvest.2015.63] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 8.0] [Reference Citation Analysis]
84 Shah SA, Smith JK, Li Y, Ng SC, Carroll JE, Tseng JF. Underutilization of therapy for hepatocellular carcinoma in the medicare population. Cancer 2011;117:1019-26. [DOI: 10.1002/cncr.25683] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
85 Simsek E, Lu X, Ouzounov S, Block TM, Mehta AS. α-Glucosidase Inhibitors Have a Prolonged Antiviral Effect against Hepatitis B Virus through the Sustained Inhibition of the Large and Middle Envelope Glycoproteins. Antivir Chem Chemother 2006;17:259-67. [DOI: 10.1177/095632020601700503] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
86 Dávalos Moscol M, Bustios Sanchez C. The burden of hepatic encephalopathy in Latin America. Annals of Hepatology 2011;10:S31-5. [DOI: 10.1016/s1665-2681(19)31603-5] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
87 Trerè D, Borzio M, Morabito A, Borzio F, Roncalli M, Derenzini M. Nucleolar hypertrophy correlates with hepatocellular carcinoma development in cirrhosis due to HBV infection. Hepatology 2003;37:72-8. [PMID: 12500191 DOI: 10.1053/jhep.2003.50039] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
88 Marrero JA, Welling T. Modern Diagnosis and Management of Hepatocellular Carcinoma. Clinics in Liver Disease 2009;13:233-47. [DOI: 10.1016/j.cld.2009.02.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
89 Chen D, Jain S, Su YH, Song W. Building Classification Models with Combined Biomarker Tests: Application to Early Detection of Liver Cancer. J Stat Sci Appl 2017;5:91-103. [PMID: 29152526 DOI: 10.17265/2328-224X/2017.0506.002] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
90 Masuda T, Miyoshi E. Cancer biomarkers for hepatocellular carcinomas: from traditional markers to recent topics. Clin Chem Lab Med 2011;49:959-66. [PMID: 21428856 DOI: 10.1515/CCLM.2011.152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
91 Jansen PL. Liver disease in the elderly. Best Pract Res Clin Gastroenterol. 2002;16:149-158. [PMID: 11977934 DOI: 10.1053/bega.2002.0271] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
92 Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-107. [DOI: 10.1038/sj.onc.1206557] [Cited by in Crossref: 350] [Cited by in F6Publishing: 332] [Article Influence: 18.4] [Reference Citation Analysis]
93 Du J, Hong J, Xu C, Cai Y, Xiang B, Zhou C, Xu X. Screening and Identification of ssDNA Aptamer for Human GP73. Biomed Res Int 2015;2015:610281. [PMID: 26583119 DOI: 10.1155/2015/610281] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
94 Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y, Kondo T. Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics 2016;13:28. [PMID: 27799868 DOI: 10.1186/s12014-016-9130-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
95 Gelatti U, Donato F, Tagger A, Fantoni C, Portolani N, Ribero ML, Martelli C, Trevisi P, Covolo L, Simonati C, Nardi G; Brescia HCC Study. Etiology of hepatocellular carcinoma influences clinical and pathologic features but not patient survival. Am J Gastroenterol 2003;98:907-14. [PMID: 12738476 DOI: 10.1111/j.1572-0241.2003.t01-1-07289.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
96 Huang D, Zhang W, Huang D, Wu J. Antitumor activity of the aqueous extract from Sedum sarmentosum Bunge in vitro. Cancer Biother Radiopharm. 2010;25:81-88. [PMID: 20187800 DOI: 10.1089/cbr.2009.0632] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
97 Reynaert H, Rombouts K, Vandermonde A, Urbain D, Kumar U, Bioulac-Sage P, Pinzani M, Rosenbaum J, Geerts A. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004;53:1180-9. [PMID: 15247189 DOI: 10.1136/gut.2003.036053] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 4.4] [Reference Citation Analysis]
98 Ramadori G, Füzesi L, Grabbe E, Pieler T, Armbrust T. Successful treatment of hepatocellular carcinoma with the tyrosine kinase inhibitor imatinib in a patient with liver cirrhosis. Anticancer Drugs. 2004;15:405-409. [PMID: 15057146 DOI: 10.1097/00001813-200404000-00014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.5] [Reference Citation Analysis]
99 Blum HE, Moradpour D. Viral pathogenesis of hepatocellular carcinoma. J Gastroenterol Hepatol. 2002;17 Suppl 3:S413-S420. [PMID: 12472973 DOI: 10.1046/j.1440-1746.17.s3.37.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
100 Teschke R. Alkoholische Lebererkrankungen. Klinische Hepatologie. Berlin: Springer Berlin Heidelberg; 2003. pp. 609-58. [DOI: 10.1007/978-3-642-55902-0_28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
102 Berber E, Rogers S, Siperstein A. Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study. Surg Endosc 2005;19:710-4. [PMID: 15759186 DOI: 10.1007/s00464-004-8815-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 2.1] [Reference Citation Analysis]
103 El-serag H, Kramer JR. Hepatitis C infection: Dying with or from the infection? Journal of Hepatology 2008;48:183-4. [DOI: 10.1016/j.jhep.2007.11.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
104 Gruden G, Carucci P, Lolli V, Cosso L, Dellavalle E, Rolle E, Cantamessa A, Pinach S, Abate ML, Campra D. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress Chaperones. 2013;18:235-241. [PMID: 23073653 DOI: 10.1007/s12192-012-0377-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
105 Ahn J, Flamm SL. Hepatocellular carcinoma. Dis Mon 2004;50:556-73. [PMID: 15616490 DOI: 10.1016/j.disamonth.2004.10.001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
106 Dohmen K, Shigematsu H, Irie K, Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol. 2003;18:267-272. [PMID: 12603526 DOI: 10.1046/j.1440-1746.2003.02936.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
107 Yang H, Lin M, Xiong F, Yang Y, Nie X, McNutt MA, Zhou R. Combined lysosomal protein transmembrane 4 beta-35 and argininosuccinate synthetase expression predicts clinical outcome in hepatocellular carcinoma patients. Surg Today 2011;41:810-7. [PMID: 21626328 DOI: 10.1007/s00595-010-4338-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
108 Höpfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherübl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol. 2004;41:1008-1016. [PMID: 15582135 DOI: 10.1016/j.jhep.2004.08.024] [Cited by in Crossref: 123] [Cited by in F6Publishing: 123] [Article Influence: 7.2] [Reference Citation Analysis]
109 Arrieta O, Rodriguez-Diaz JL, Rosas-Camargo V, Morales-Espinosa D, Ponce de Leon S, Kershenobich D, Leon-Rodriguez E. Colchicine delays the development of hepatocellular carcinoma in patients with hepatitis virus-related liver cirrhosis. Cancer 2006;107:1852-8. [PMID: 16967451 DOI: 10.1002/cncr.22198] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
110 Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A. 2005;102:779-784. [PMID: 15642945 DOI: 10.1073/pnas.0408928102] [Cited by in Crossref: 264] [Cited by in F6Publishing: 262] [Article Influence: 15.5] [Reference Citation Analysis]
111 Trevisani F, Santi V, Gramenzi A, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M; Italian Liver Cancer Group. Surveillance for early diagnosis of hepatocellular carcinoma: is it effective in intermediate/advanced cirrhosis? Am J Gastroenterol 2007;102:2448-57; quiz 2458. [PMID: 17617210 DOI: 10.1111/j.1572-0241.2007.01395.x] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
112 Lopez LJ, Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2004;20:248-53. [DOI: 10.1097/00001574-200405000-00009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
113 Deuffic-Burban S, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974-985.e14. [PMID: 22863764 DOI: 10.1053/j.gastro.2012.05.054] [Cited by in Crossref: 90] [Cited by in F6Publishing: 89] [Article Influence: 9.0] [Reference Citation Analysis]
114 Izzo F, Marra P, Beneduce G, Castello G, Vallone P, De Rosa V, Cremona F, Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA, Ng C, Curley SA. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol. 2004;22:1815-1822. [PMID: 15143074 DOI: 10.1200/jco.2004.11.120] [Cited by in Crossref: 182] [Cited by in F6Publishing: 83] [Article Influence: 10.1] [Reference Citation Analysis]
115 Salem R, Lewandowski R, Roberts C, Goin J, Thurston K, Abouljoud M, Courtney A. Use of Yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol. 2004;15:335-345. [PMID: 15064336 DOI: 10.1097/01.rvi.0000123319.20705.92] [Cited by in Crossref: 150] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
116 Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54:2031-2039. [PMID: 19117131 DOI: 10.1007/s10620-008-0661-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
117 Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015;61:191-9. [PMID: 25142309 DOI: 10.1002/hep.27388] [Cited by in Crossref: 343] [Cited by in F6Publishing: 323] [Article Influence: 49.0] [Reference Citation Analysis]
118 Deuffic-Burban S, Babany G, Lonjon-Domanec I, Deltenre P, Canva-Delcambre V, Dharancy S, Louvet A, Roudot-Thoraval F, Mathurin P. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France. Hepatology 2009;50:1351-9. [PMID: 19676130 DOI: 10.1002/hep.23159] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
119 Wang Y, Luo F, Zheng Y, Fan X, Chen J, Zhang Y, Hui R. VKORC1 haplotypes influence the performance characteristics of PIVKAII for screening of hepatocellular carcinoma. Clin Chem Lab Med 2010;48:1475-9. [PMID: 20575749 DOI: 10.1515/CCLM.2010.275] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
120 Salem N, Kuang Y, Corn D, Erokwu B, Kolthammer JA, Tian H, Wu C, Wang F, Wang Y, Lee Z. [(Methyl)1-(11)c]-acetate metabolism in hepatocellular carcinoma. Mol Imaging Biol. 2011;13:140-151. [PMID: 20401538 DOI: 10.1007/s11307-010-0308-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
121 Borzio M, Dionigi E, Rossini A, Toldi A, Francica G, Fornari F, Salmi A, Farinati F, Vicari S, Marignani M. Trend of improving prognosis of hepatocellular carcinoma in clinical practice: an italian in-field experience. Dig Dis Sci. 2015;60:1465-1473. [PMID: 25399329 DOI: 10.1007/s10620-014-3427-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
122 Luo DL, Yang D, Shu ML, Deng MM. Anticancer mechanisms of resveratrol in liver cancer. Shijie Huaren Xiaohua Zazhi 2014; 22(31): 4769-4773 [DOI: 10.11569/wcjd.v22.i31.4769] [Reference Citation Analysis]
123 Shi L, Feng Y, Lin H, Ma R, Cai X. Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 2014;12:93. [PMID: 24708807 DOI: 10.1186/1479-5876-12-93] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 8.0] [Reference Citation Analysis]
124 Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O, Antonaci S. Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 2002;161:183-93. [PMID: 12107103 DOI: 10.1016/s0002-9440(10)64170-3] [Cited by in Crossref: 118] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
125 Ramakrishnan G, Jagan S, Kamaraj S, Anandakumar P, Devaki T. Silymarin attenuated mast cell recruitment thereby decreased the expressions of matrix metalloproteinases-2 and 9 in rat liver carcinogenesis. Invest New Drugs 2009;27:233-40. [DOI: 10.1007/s10637-008-9163-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.6] [Reference Citation Analysis]
126 Casadei Gardini A, Faloppi L, De Matteis S, Foschi FG, Silvestris N, Tovoli F, Palmieri V, Marisi G, Brunetti O, Vespasiani-Gentilucci U, Perrone G, Valgiusti M, Granato AM, Ercolani G, Negrini G, Tamburini E, Aprile G, Passardi A, Santini D, Cascinu S, Frassineti GL, Scartozzi M. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. Eur J Cancer 2017;86:106-14. [PMID: 28985579 DOI: 10.1016/j.ejca.2017.09.003] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 10.0] [Reference Citation Analysis]
127 Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg. 2008;195:829-836. [PMID: 18436176 DOI: 10.1016/j.amjsurg.2007.10.010] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 5.4] [Reference Citation Analysis]
128 Carr BI, Kanke F, Wise M, Satomura S. Clinical Evaluation of Lens Culinaris Agglutinin-Reactive α-Fetoprotein and Des-γ-Carboxy Prothrombin in Histologically Proven Hepatocellular Carcinoma in the United States. Dig Dis Sci 2007;52:776-82. [DOI: 10.1007/s10620-006-9541-2] [Cited by in Crossref: 90] [Cited by in F6Publishing: 81] [Article Influence: 6.0] [Reference Citation Analysis]
129 Hassoun Z, Gores GJ. What surgeons should know about viral hepatitis and hepatocellular carcinoma. Surg Oncol Clin N Am. 2003;12:1-11. [PMID: 12735125 DOI: 10.1016/S1055-3207(02)00081-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
130 Wei S, Liu W, Sun N, Wu Y, Song H, Wang C, Wang S, Zou R, Lin L, Zeng K, Zhou B, Wang M, Luan R, Yang F, Zhao Y. MOF upregulates the estrogen receptor α signaling pathway by its acetylase activity in hepatocellular carcinoma. Cancer Sci 2021;112:1865-77. [PMID: 33544437 DOI: 10.1111/cas.14836] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
131 Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, Matthews TA, Nagorney DM, Cunningham JM, Smith DI. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology. 2004;126:231-248. [PMID: 14699503 DOI: 10.1053/j.gastro.2003.09.043] [Cited by in Crossref: 111] [Cited by in F6Publishing: 111] [Article Influence: 6.2] [Reference Citation Analysis]
132 Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-21. [PMID: 12717392 DOI: 10.1053/jhep.2003.50195] [Cited by in Crossref: 280] [Cited by in F6Publishing: 248] [Article Influence: 14.7] [Reference Citation Analysis]
133 Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008;48:1149-56. [PMID: 18785621 DOI: 10.1002/hep.22458] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.7] [Reference Citation Analysis]
134 Miao X, Liu G, Xu X, Xie C, Sun F, Yang Y, Zhang T, Hua S, Fan W, Li Q, Huang S, Wang Q, Liu G, Zhong D. High expression of vanilloid receptor-1 is associated with better prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2008;186:25-32. [PMID: 18786439 DOI: 10.1016/j.cancergencyto.2008.05.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
135 Rudow D. Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. Liver Transplantation 2003;9:254-9. [DOI: 10.1053/jlts.2003.50037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
136 Gogia S, Befeler AS. Treating hepatocellular carcinoma without liver transplantation. Curr Gastroenterol Rep 2009;11:69-75. [PMID: 19166662 DOI: 10.1007/s11894-009-0011-9] [Reference Citation Analysis]
137 Zhao M, Dong G, Meng Q, Lin S, Li X. Circ-HOMER1 enhances the inhibition of miR-1322 on CXCL6 to regulate the growth and aggressiveness of hepatocellular carcinoma cells. J Cell Biochem 2020;121:4440-9. [PMID: 32037619 DOI: 10.1002/jcb.29672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
138 Trevisani F, Cantarini MC, Wands JR, Bernardi M. Recent advances in the natural history of hepatocellular carcinoma. Carcinogenesis. 2008;1299-1305. [PMID: 18515282 DOI: 10.1093/carcin/bgn113] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 7.5] [Reference Citation Analysis]
139 El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004;127:S27-S34. [PMID: 15508094 DOI: 10.1053/j.gastro.2004.09.013] [Cited by in Crossref: 718] [Cited by in F6Publishing: 662] [Article Influence: 39.9] [Reference Citation Analysis]
140 Comunale MA, Wang M, Rodemich-Betesh L, Hafner J, Lamontagne A, Klein A, Marrero J, Di Bisceglie AM, Gish R, Block T, Mehta A. Novel changes in glycosylation of serum Apo-J in patients with hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2011;20:1222-9. [PMID: 21467232 DOI: 10.1158/1055-9965.EPI-10-1047] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
141 Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med 2008;121:525-31. [PMID: 18501235 DOI: 10.1016/j.amjmed.2008.03.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
142 Mathurin P, Raynard B, Dharancy S, Kirzin S, Fallik D, Pruvot F, Roumilhac D, Canva V, Paris J, Chaput J, Naveau S. Meta-analysis: evaluation of adjuvant therapy after curative liver resection for hepatocellular carcinoma: META-ANALYSIS: ADJUVANT THERAPY AFTER CURATIVE LIVER RESECTION FOR HCC. Alimentary Pharmacology & Therapeutics 2003;17:1247-61. [DOI: 10.1046/j.1365-2036.2003.01580.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 80] [Article Influence: 4.0] [Reference Citation Analysis]
143 Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. Journal of Hepatology 2003;38:136-49. [DOI: 10.1016/s0168-8278(02)00432-4] [Cited by in Crossref: 156] [Cited by in F6Publishing: 56] [Article Influence: 8.2] [Reference Citation Analysis]
144 Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, Meng ZQ, Feng Y. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003; 9(8): 1697-1701 [PMID: 12918103 DOI: 10.3748/wjg.v9.i8.1697] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
145 Artinyan A, Mailey B, Sanchez-Luege N, Khalili J, Sun CL, Bhatia S, Wagman LD, Nissen N, Colquhoun SD, Kim J. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer. 2010;116:1367-1377. [PMID: 20101732 DOI: 10.1002/cncr.24817] [Cited by in Crossref: 150] [Cited by in F6Publishing: 150] [Article Influence: 12.5] [Reference Citation Analysis]
146 Feng JT, Shang S, Beretta L. Proteomics for the early detection and treatment of hepatocellular carcinoma. Oncogene. 2006;25:3810-3817. [PMID: 16799622 DOI: 10.1038/sj.onc.1209551] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
147 Barone M, Maiorano E, Scavo M, Panella E, Castellaneta A, Napoli A, Francioso D, Di Leo A, Francavilla A. Effect of gonadectomy on HCC development in HBV transgenic mice. Digestive and Liver Disease 2009;41:150-5. [DOI: 10.1016/j.dld.2008.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
148 Wu H, Yao S, Zhang S, Wang JR, Guo PD, Li XM, Gan WJ, Mei L, Gao TM, Li JM. Elevated expression of Erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma. J Hepatol 2017;66:1193-204. [PMID: 28192186 DOI: 10.1016/j.jhep.2017.01.030] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
149 Comunale MA, Rodemich-Betesh L, Hafner J, Wang M, Norton P, Di Bisceglie AM, Block T, Mehta A. Linkage specific fucosylation of alpha-1-antitrypsin in liver cirrhosis and cancer patients: Implications for a biomarker of hepatocellular carcinoma. PLoS One. 2010;5:e12419. [PMID: 20811639 DOI: 10.1371/journal.pone.0012419] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 7.7] [Reference Citation Analysis]
150 Siegel AB, McBride RB, El-Serag HB, Hershman D, Brown RS Jr, Zablotska L, Neugut AI. The risk of hepatocellular carcinoma in patients with previous malignancy. Cancer Invest 2008;26:511-5. [PMID: 18568774 DOI: 10.1080/07357900701788007] [Reference Citation Analysis]
151 Kawakami T, Hoshida Y, Kanai F, Tanaka Y, Tateishi K, Ikenoue T, Obi S, Sato S, Teratani T, Shiina S. Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment. Proteomics. 2005;5:4287-4295. [PMID: 16254924 DOI: 10.1002/pmic.200401287] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 2.5] [Reference Citation Analysis]
152 Szabó E, Páska C, Kaposi Novák P, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol Oncol Res 2004;10:5-11. [PMID: 15029254 DOI: 10.1007/BF02893401] [Cited by in Crossref: 66] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
153 Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 198] [Article Influence: 14.2] [Reference Citation Analysis]
154 Kemp W, Pianko S, Nguyen S, Bailey MJ, Roberts SK. Survival in hepatocellular carcinoma: impact of screening and etiology of liver disease. J Gastroenterol Hepatol. 2005;20:873-881. [PMID: 15946134 DOI: 10.1111/j.1440-1746.2005.03844.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 2.8] [Reference Citation Analysis]
155 Kalva SP, Thabet A, Wicky S. Recent advances in transarterial therapy of primary and secondary liver malignancies. Radiographics. 2008;28:101-117. [PMID: 18203933 DOI: 10.1148/rg.281075115] [Cited by in Crossref: 43] [Cited by in F6Publishing: 34] [Article Influence: 3.1] [Reference Citation Analysis]
156 Torres-poveda K, Burguete-garcía AI, Madrid-marina V. Liver cirrhosis and hepatocellular carcinoma in Mexico: impact of chronic infection by hepatitis viruses B and C. Annals of Hepatology 2011;10:556-8. [DOI: 10.1016/s1665-2681(19)31525-x] [Cited by in Crossref: 9] [Article Influence: 0.8] [Reference Citation Analysis]
157 Deuffic-Burban S, Deltenre P, Louvet A, Canva V, Dharancy S, Hollebecque A, Boitard J, Henrion J, Yazdanpanah Y, Mathurin P. Impact of viral eradication on mortality related to hepatitis C: a modeling approach in France. J Hepatol. 2008;49:175-183. [PMID: 18538441 DOI: 10.1016/j.jhep.2008.04.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
158 Wang CS, Lin CL, Lee HC, Chen KY, Chiang MF, Chen HS, Lin TJ, Liao LY. Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma. World J Gastroenterol 2005; 11(39): 6115-6119 [PMID: 16273636 DOI: 10.3748/wjg.v11.i39.6115] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 62] [Article Influence: 3.8] [Reference Citation Analysis]
159 Christie JK, Tilocca A. Molecular Dynamics Simulations and Structural Descriptors of Radioisotope Glass Vectors for In Situ Radiotherapy. J Phys Chem B 2012;116:12614-20. [DOI: 10.1021/jp304200f] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
160 Fontana RJ, Hamidullah H, Nghiem H, Greenson JK, Hussain H, Marrero J, Rudich S, McClure LA, Arenas J. Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation. Liver Transpl. 2002;8:1165-1174. [PMID: 12474157 DOI: 10.1053/jlts.2002.36394] [Cited by in Crossref: 117] [Cited by in F6Publishing: 114] [Article Influence: 6.2] [Reference Citation Analysis]
161 Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20:1669-1676. [PMID: 19578008 DOI: 10.1681/asn.2008070782] [Cited by in Crossref: 133] [Cited by in F6Publishing: 80] [Article Influence: 10.2] [Reference Citation Analysis]
162 Krishnan V, Subramaniam S, Chia-Chuan C, Venkatachalam B, Thomas Cheeran A, Chi-Ying F H. Anticancer Activity of Leonurus sibiricus L.: Possible Involvement of Intrinsic Apoptotic Pathway. Nutr Cancer 2021;:1-12. [PMID: 33432822 DOI: 10.1080/01635581.2020.1870702] [Reference Citation Analysis]
163 Keppke AL, Salem R, Reddy D, Huang J, Jin J, Larson AC, Miller FH. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR Am J Roentgenol. 2007;188:768-775. [PMID: 17312067 DOI: 10.2214/ajr.06.0706] [Cited by in Crossref: 87] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
164 Watanabe Y, Iwamura A, Shimada YJ, Wakai K, Tamakoshi A, Iso H; JACC Study Group. Transforming Growth Factor-β1 as a Predictor for the Development of Hepatocellular Carcinoma: A Nested Case-Controlled Study. EBioMedicine 2016;12:68-71. [PMID: 27614396 DOI: 10.1016/j.ebiom.2016.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
165 Marrero CR, Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. Archives of Medical Research 2007;38:612-20. [DOI: 10.1016/j.arcmed.2006.09.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
166 Corona-Villalobos CP, Zhang Y, Zhang WD, Kamel IR. Magnetic resonance imaging of the liver after loco-regional and systemic therapy. Magn Reson Imaging Clin N Am 2014;22:353-72. [PMID: 25086934 DOI: 10.1016/j.mric.2014.04.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
167 Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7:35-41. [PMID: 18333159 DOI: 10.1080/13651820410024058] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 12.8] [Reference Citation Analysis]
168 Thein HH, Khoo E, Campitelli MA, Zaheen A, Yi Q, De P, Earle CC. Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open 2015;3:E208-16. [PMID: 26389099 DOI: 10.9778/cmajo.20140118] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
169 Casadei Gardini A, Marisi G, Scarpi E, Scartozzi M, Faloppi L, Silvestris N, Masi G, Vivaldi C, Brunetti O, Tamberi S. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. Expert Opin Pharmacother. 2015;16:2719-2725. [PMID: 26513009 DOI: 10.1517/14656566.2015.1102887] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
170 Tan TL, Chen WN. A proteomics analysis of cellular proteins associated with HBV genotype-specific HBX: potential in identification of early diagnostic markers for HCC. J Clin Virol 2005;33:293-8. [PMID: 16036179 DOI: 10.1016/j.jcv.2004.12.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
171 Jiang M, Klein M, Zanger UM, Mohammad MK, Cave MC, Gaikwad NW, Dias NJ, Selcer KW, Guo Y, He J, Zhang X, Shen Q, Qin W, Li J, Li S, Xie W. Inflammatory regulation of steroid sulfatase: A novel mechanism to control estrogen homeostasis and inflammation in chronic liver disease. J Hepatol 2016;64:44-52. [PMID: 26220752 DOI: 10.1016/j.jhep.2015.07.022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
172 Wong LL, Limm WM, Tsai N, Severino R. Hepatitis B and alcohol affect survival of hepatocellular carcinoma patients. World J Gastroenterol 2005; 11(23): 3491-3497 [PMID: 15962361 DOI: 10.3748/wjg.v11.i23.3491] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
173 Chignard N, Shang S, Wang H, Marrero J, Bréchot C, Hanash S, Beretta L. Cleavage of Endoplasmic Reticulum Proteins in Hepatocellular Carcinoma: Detection of Generated Fragments in Patient Sera. Gastroenterology 2006;130:2010-22. [DOI: 10.1053/j.gastro.2006.02.058] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
174 Chen X, Higgins J, Cheung ST, Li R, Mason V, Montgomery K, Fan ST, van de Rijn M, So S. Novel endothelial cell markers in hepatocellular carcinoma. Mod Pathol 2004;17:1198-210. [PMID: 15154008 DOI: 10.1038/modpathol.3800167] [Cited by in Crossref: 65] [Cited by in F6Publishing: 58] [Article Influence: 3.8] [Reference Citation Analysis]
175 Liu CY, Liao HF, Shih SC, Lin SC, Chang WH, Chu CH, Wang TE, Chen YJ. Colchicine sensitizes human hepatocellular carcinoma cells to damages caused by radiation. World J Gastroenterol 2005; 11(27): 4237-4240 [PMID: 16015697 DOI: 10.3748/wjg.v11.i27.4237] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
176 Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, Höpfner M, Krahn A, Heine B, Stein H, Somasundaram R. Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol. 2004;41:799-807. [PMID: 15519653 DOI: 10.1016/j.jhep.2004.07.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 2.0] [Reference Citation Analysis]
177 Rakela J. Hepatitis C: Magnitude of the problem. Liver Transplantation 2002;8:S3-6. [DOI: 10.1053/jlts.2002.35855] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
178 Deuffic-burban S, Wong JB, Valleron A, Costagliola D, Delfraissy J, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. Journal of Hepatology 2004;40:319-26. [DOI: 10.1016/j.jhep.2003.10.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
179 Liu Y, Hong Z, Tan G, Dong X, Yang G, Zhao L, Chen X, Zhu Z, Lou Z, Qian B, Zhang G, Chai Y. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Int J Cancer 2014;135:658-68. [PMID: 24382646 DOI: 10.1002/ijc.28706] [Cited by in Crossref: 73] [Cited by in F6Publishing: 73] [Article Influence: 9.1] [Reference Citation Analysis]
180 Wan C, Fang J, Yang Z, Zhang C, Luo J, Meng Q, Jiang D. Development and validation of a quality of life instrument for patients with liver cancer QOL-LC. Am J Clin Oncol 2010;33:448-55. [PMID: 19935384 DOI: 10.1097/COC.0b013e3181b4b04f] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
181 Fujita K, Iwama H, Miyoshi H, Tani J, Oura K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, Masaki T. Diabetes mellitus and metformin in hepatocellular carcinoma. World J Gastroenterol 2016; 22(27): 6100-6113 [PMID: 27468203 DOI: 10.3748/wjg.v22.i27.6100] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
182 Bhalla K, Hwang BJ, Dewi RE, Twaddel W, Goloubeva OG, Wong KK, Saxena NK, Biswal S, Girnun GD. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila). 2012;5:544-552. [PMID: 22467080 DOI: 10.1158/1940-6207.CAPR-11-0228.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Schwegler EE, Cazares L, Steel LF, Adam BL, Johnson DA, Semmes OJ, Block TM, Marrero JA, Drake RR. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma. Hepatology 2005;41:634-42. [PMID: 15726646 DOI: 10.1002/hep.20577] [Cited by in Crossref: 110] [Cited by in F6Publishing: 98] [Article Influence: 6.5] [Reference Citation Analysis]
184 Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012;55:476-82. [PMID: 21953588 DOI: 10.1002/hep.24710] [Cited by in Crossref: 174] [Cited by in F6Publishing: 168] [Article Influence: 17.4] [Reference Citation Analysis]
185 El-serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001;96:2462-7. [DOI: 10.1111/j.1572-0241.2001.04054.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 166] [Article Influence: 8.8] [Reference Citation Analysis]
186 Xu H, Wei Y, Zhang Y, Xu Y, Li F, Liu J, Zhang W, Han X, Tan R, Shen P. Oestrogen attenuates tumour progression in hepatocellular carcinoma. J Pathol 2012;228:216-29. [PMID: 22374713 DOI: 10.1002/path.4009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
187 Wong LL, Tsai N. Hepatocellular carcinoma in Filipinos. Asia-Pacific J Clinical Oncology 2007;3:84-8. [DOI: 10.1111/j.1743-7563.2007.00091.x] [Reference Citation Analysis]
188 Zhao QT, Yue SQ, Cui Z, Wang Q, Cui X, Zhai HH, Zhang LH, Dou KF. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. Life Sci. 2007;80:484-492. [PMID: 17097688 DOI: 10.1016/j.lfs.2006.09.038] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
189 Mehta A, Norton P, Liang H, Comunale MA, Wang M, Rodemich-Betesh L, Koszycki A, Noda K, Miyoshi E, Block T. Increased levels of tetra-antennary N-linked glycan but not core fucosylation are associated with hepatocellular carcinoma tissue. Cancer Epidemiol Biomarkers Prev. 2012;21:925-933. [PMID: 22490318 DOI: 10.1158/1055-9965.epi-11-1183] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 4.2] [Reference Citation Analysis]
190 Marrero JA. Modern diagnosis of hepatocellular carcinoma: Utilization of liver biopsy and genomic markers. Journal of Hepatology 2009;50:659-61. [DOI: 10.1016/j.jhep.2009.01.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
191 Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005;100:56-63. [PMID: 15654781 DOI: 10.1111/j.1572-0241.2005.40670.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 107] [Article Influence: 6.6] [Reference Citation Analysis]
192 Winters AC, Sung JC, Wyatt B, Berera D, Schiano TD, Schwartz ME, Perumalswami PV, Branch AD. At diagnosis of hepatocellular carcinoma, African Americans with hepatitis C have better liver function than other patients. Clin Liver Dis (Hoboken) 2018;12:109-12. [PMID: 30416720 DOI: 10.1002/cld.745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
193 Cui W, Hu SX, Tang ZY, Hu KQ. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice. Anticancer Drugs. 2008;19:891-897. [PMID: 18766003 DOI: 10.1097/CAD.0b013e32830ef8ca] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
194 Arguedas MR. Screening for hepatocellular carcinoma: Why, when, how? Curr Gastroenterol Rep 2003;5:57-62. [DOI: 10.1007/s11894-003-0010-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Enriquez AD, Campbell MS, Reddy KR. Cost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosis: TREATMENT OF IMMUNE TOLERANT HBV. Alimentary Pharmacology & Therapeutics 2007;26:383-91. [DOI: 10.1111/j.1365-2036.2007.03382.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
196 Alsohaibani F, Porter G, Al-Ashgar H, Walsh M, Berry R, Molinari M, Peltekian KM. Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. J Gastrointest Cancer 2011;42:228-35. [PMID: 20809396 DOI: 10.1007/s12029-010-9200-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
197 Pearlman BL, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis. 2011;52:889-900. [PMID: 21427396 DOI: 10.1093/cid/cir076] [Cited by in Crossref: 161] [Cited by in F6Publishing: 161] [Article Influence: 14.6] [Reference Citation Analysis]
198 Lu JW, Sun Y, Lin LI, Liu D, Gong Z. Exacerbation of Liver Tumor Metastasis in twist1a+/xmrk+ Double Transgenic Zebrafish following Lipopolysaccharide or Dextran Sulphate Sodium Exposure. Pharmaceuticals (Basel) 2021;14:867. [PMID: 34577566 DOI: 10.3390/ph14090867] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Ma SJ, Zheng YX, Zhou PC, Xiao YN, Tan HZ. Metformin use improves survival of diabetic liver cancer patients: systematic review and meta-analysis. Oncotarget. 2016;7:66202-66211. [PMID: 27494848 DOI: 10.18632/oncotarget.11033] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 7.5] [Reference Citation Analysis]
200 Lu JW, Yang WY, Lin YM, Jin SL, Yuh CH. Hepatitis B virus X antigen and aflatoxin B1 synergistically cause hepatitis, steatosis and liver hyperplasia in transgenic zebrafish. Acta Histochem 2013;115:728-39. [PMID: 23499292 DOI: 10.1016/j.acthis.2013.02.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
201 Moya A, Berenguer M, Aguilera V, Juan FS, Nicolás D, Pastor M, López-Andujar R, Rayón M, Orbis F, Mora J. Hepatocellular carcinoma: Can it be considered a controversial indication for liver transplantation in centers with high rates of hepatitis C? Liver Transpl. 2002;8:1020-1027. [PMID: 12424715 DOI: 10.1053/jlts.2002.35664] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
202 Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, Stadheim LM, Aderca I, Moser CD, Nagorney DM, LaRusso NF, de Groen PC, Menon KV, Lazaridis KN, Gores GJ, Charlton MR, Roberts RO, Therneau TM, Katzmann JA, Roberts LR. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007;5:394-402; quiz 267. [PMID: 17368240 DOI: 10.1016/j.cgh.2006.12.005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 5.1] [Reference Citation Analysis]
203 Thabet A, Kalva S, Gervais DA. Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdom Imaging 2009;34:593-609. [DOI: 10.1007/s00261-008-9448-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
204 Rhee TK, Omary RA, Gates V, Mounajjed T, Larson AC, Barakat O, Sato KT, Mulcahy M, Gordon S, Lewandowski RJ, Salem R. The Effect of Catheter-Directed CT Angiography on Yttrium-90 Radioembolization Treatment of Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2005;16:1085-91. [DOI: 10.1097/01.rvi.0000177063.92678.21] [Cited by in Crossref: 49] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
205 Marrero JA. Viral Hepatitis and Hepatocellular Carcinoma. In: Shetty K, Wu GY, editors. Chronic Viral Hepatitis. Totowa: Humana Press; 2010. pp. 431-47. [DOI: 10.1007/978-1-59745-565-7_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
206 Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, Van Buskirk M, Roberts CA, Goin JE. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127:S194-S205. [PMID: 15508085 DOI: 10.1053/j.gastro.2004.09.034] [Cited by in Crossref: 241] [Cited by in F6Publishing: 210] [Article Influence: 13.4] [Reference Citation Analysis]
207 Wong LL. Current status of liver transplantation for hepatocellular cancer. Am J Surg. 2002;183:309-316. [PMID: 11943133 DOI: 10.1016/s0002-9610(02)00785-7] [Cited by in Crossref: 39] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
208 McCarty TR, Njei B. Trends in malignant intraductal papillary mucinous neoplasm in US adults from 1990 to 2010: a SEER database analysis. Gastroenterol Rep (Oxf) 2016;4:113-8. [PMID: 26818977 DOI: 10.1093/gastro/gov066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
209 Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg. 2005;29:1364-1373. [PMID: 16240062 DOI: 10.1007/s00268-005-7829-6] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.4] [Reference Citation Analysis]
210 Liu YH, Jin JL, Wang YZ, Tan Y, Zhou YY, Peng T, Li F, Liang WD, Chartrand P, Jiang YY, Shen ZF. Protrusion-localized STAT3 mRNA promotes metastasis of highly metastatic hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin 2016;37:805-13. [PMID: 27133294 DOI: 10.1038/aps.2015.166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
211 Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg. 2004;187:181-191. [PMID: 14769302 DOI: 10.1016/j.amjsurg.2003.11.016] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 6.2] [Reference Citation Analysis]
212 Wang G, Dong F, Xu Z, Sharma S, Hu X, Chen D, Zhang L, Zhang J, Dong Q. MicroRNA profile in HBV-induced infection and hepatocellular carcinoma. BMC Cancer. 2017;17:805. [PMID: 29191172 DOI: 10.1186/s12885-017-3816-1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
213 Cao W, Wan Y, Liang ZH, Duan YY, Liu X, Wang ZM, Liu YY, Zhu J, Liu XT, Zhang HX. Heated lipiodol as an embolization agent for transhepatic arterial embolization in VX2 rabbit liver cancer model. Eur J Radiol. 2010;73:412-419. [PMID: 19091502 DOI: 10.1016/j.ejrad.2008.11.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
214 Barone M, Margiotta M, Scavo MP, Gentile A, Francioso D, Papagni S, Castellaneta A, Mallamaci R, Di Leo A, Francavilla A. Possible involvement of androgen receptor alterations in hepatocarcinogenesis. Dig Liver Dis 2009;41:665-70. [PMID: 19201267 DOI: 10.1016/j.dld.2008.12.099] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
215 Cui XD, Lee MJ, Yu GR, Kim IH, Yu HC, Song EY, Kim DG. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer 2010;126:940-9. [PMID: 19642143 DOI: 10.1002/ijc.24798] [Cited by in Crossref: 12] [Cited by in F6Publishing: 36] [Article Influence: 1.0] [Reference Citation Analysis]
216 Guo WJ, Li J, Ling WL, Bai YR, Zhang WZ, Cheng YF, Gu WH, Zhuang JY. Influence of hepatic arterial blockage on blood perfusion and VEGF, MMP-1 expression of implanted liver cancer in rats. World J Gastroenterol 2002; 8(3): 476-479 [PMID: 12046073 DOI: 10.3748/wjg.v8.i3.476] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
217 Robbins AS, Daily MF, Aoki CA, Chen MS Jr, Troppmann C, Perez RV. Decreasing disparity in liver transplantation among white and Asian patients with hepatocellular carcinoma: California, 1998-2005. Cancer. 2008;113:2173-2179. [PMID: 18792066 DOI: 10.1002/cncr.23766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
218 Lim SC, Choi JE, Kang HS, Han SI. Ursodeoxycholic acid switches oxaliplatin-induced necrosis to apoptosis by inhibiting reactive oxygen species production and activating p53-caspase 8 pathway in HepG2 hepatocellular carcinoma. Int J Cancer 2010;126:1582-95. [PMID: 19728331 DOI: 10.1002/ijc.24853] [Cited by in Crossref: 12] [Cited by in F6Publishing: 26] [Article Influence: 1.0] [Reference Citation Analysis]
219 Amarapurkar D, Han K, Chan HL, Ueno Y; The Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region. Journal of Gastroenterology and Hepatology 2009;24:955-61. [DOI: 10.1111/j.1440-1746.2009.05805.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
220 Wang Y, Liu YH, Mai SJ, He LJ, Liao YJ, Deng HX, Guan XY, Zeng YX, Kung HF, Xie D. Evaluation of serum clusterin as a surveillance tool for human hepatocellular carcinoma with hepatitis B virus related cirrhosis. J Gastroenterol Hepatol. 2010;25:1123-1128. [PMID: 20594228 DOI: 10.1111/j.1440-1746.2009.06205.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
221 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
222 Choi GH, Han S, Shim JH, Ryu MH, Ryoo BY, Kang YK, Kim KM, Lim YS, Lee HC. Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice. Am J Clin Oncol 2017;40:167-74. [PMID: 25268070 DOI: 10.1097/COC.0000000000000132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
223 Li AJ, Zhou WP, Lu JH, Cui LJ, Yang XY, Yin L, Wu MC. Surgery for pregnancy-associated primary hepatocellular carcinoma: Report of four cases. Int J Surg Case Rep 2014;5:882-5. [PMID: 25462058 DOI: 10.1016/j.ijscr.2014.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
224 Liu Y, He J, Li C, Benitez R, Fu S, Marrero J, Lubman DM. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res. 2010;9:798-805. [PMID: 19961239 DOI: 10.1021/pr900715p] [Cited by in Crossref: 54] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]
225 Chen SH, Wan QS, Zhou D, Wang T, Hu J, He YT, Yuan HL, Wang YQ, Zhang KH. A Simple-to-Use Nomogram for Predicting the Survival of Early Hepatocellular Carcinoma Patients. Front Oncol 2019;9:584. [PMID: 31355135 DOI: 10.3389/fonc.2019.00584] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
226 Fahey BJ, Nightingale KR, Nelson RC, Palmeri ML, Trahey GE. Acoustic radiation force impulse imaging of the abdomen: demonstration of feasibility and utility. Ultrasound Med Biol. 2005;31:1185-1198. [PMID: 16176786 DOI: 10.1016/j.ultrasmedbio.2005.05.004] [Cited by in Crossref: 123] [Cited by in F6Publishing: 94] [Article Influence: 7.7] [Reference Citation Analysis]
227 Thein H, Walter SR, Gidding HF, Amin J, Law MG, George J, Dore GJ. Survival after diagnosis of hepatocellular carcinoma and potential impact of treatment in a hepatitis B or C infected cohort: HCC survival in people with hepatitis B or C. Hepatology Research 2012;42:1175-86. [DOI: 10.1111/j.1872-034x.2012.01037.x] [Cited by in Crossref: 5] [Article Influence: 0.5] [Reference Citation Analysis]
228 Deuffic-Burban S, Mathurin P, Rosa I, Bouvier AM, Cannesson A, Mourad A, Canva V, Louvet A, Deltenre P, Boleslawski E. Impact of emerging hepatitis C virus treatments on future needs for liver transplantation in France: a modelling approach. Dig Liver Dis. 2014;46:157-163. [PMID: 24119483 DOI: 10.1016/j.dld.2013.08.137] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
229 Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, Coutinho R, Prins M. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam. Addiction 2012;107:614-23. [PMID: 21919987 DOI: 10.1111/j.1360-0443.2011.03654.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
230 Davila JA, El–serag HB. Racial Differences in Survival of Hepatocellular Carcinoma in the United States: A Population-Based Study. Clinical Gastroenterology and Hepatology 2006;4:104-10. [DOI: 10.1016/s1542-3565(05)00745-7] [Cited by in Crossref: 68] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
231 Spangenberg HC, Thimme R, Von Weizsäcker F, Blum HE. [Best supportive care of hepatocellular carcinoma]. Internist (Berl) 2004;45:777-85. [PMID: 15160245 DOI: 10.1007/s00108-004-1226-3] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
232 Yang M, Chen G, Dang Y, Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci. 2010;115:232-237. [PMID: 20977315 DOI: 10.3109/03009734.2010.516410] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
233 Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat. 2007;14:107-115. [PMID: 17244250 DOI: 10.1111/j.1365-2893.2006.00785.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 104] [Article Influence: 7.5] [Reference Citation Analysis]
234 Hsieh TC, Wu YC, Sun SS, Yen KY, Kao CH. Treating hepatocellular carcinoma with 90Y-bearing microspheres: a review. Biomedicine (Taipei). 2016;6:19. [PMID: 27848114 DOI: 10.7603/s40681-016-0019-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
235 Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:699-708. [PMID: 16835748 DOI: 10.1007/s00432-006-0118-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
236 Huether A, Höpfner M, Baradari V, Schuppan D, Scherübl H. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol. 2005;70:1568-1578. [PMID: 16226226 DOI: 10.1016/j.bcp.2005.09.007] [Cited by in Crossref: 111] [Cited by in F6Publishing: 105] [Article Influence: 6.5] [Reference Citation Analysis]
237 Bhat M, Yanagiya A, Graber T, Razumilava N, Bronk S, Zammit D, Zhao Y, Zakaria C, Metrakos P, Pollak M, Sonenberg N, Gores G, Jaramillo M, Morita M, Alain T. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget 2017;8:50542-56. [PMID: 28881582 DOI: 10.18632/oncotarget.10671] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
238 Ji C, Hong X, Lan B, Lin Y, He Y, Chen J, Liu X, Ye W, Mo Z, She Z, Lin S. Circ_0091581 Promotes the Progression of Hepatocellular Carcinoma Through Targeting miR-591/FOSL2 Axis. Dig Dis Sci 2021;66:3074-85. [DOI: 10.1007/s10620-020-06641-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
239 Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM, Kennedy AS, Hicks ME. Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential Complications. RadioGraphics 2005;25:S41-55. [DOI: 10.1148/rg.25si055515] [Cited by in Crossref: 228] [Cited by in F6Publishing: 189] [Article Influence: 13.4] [Reference Citation Analysis]
240 Shrimal A, Prasanth M, Kulkarni AV. Interventional radiological treatment of hepatocellular carcinoma: an update. Indian J Surg 2012;74:91-9. [PMID: 23372313 DOI: 10.1007/s12262-011-0377-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
241 Jian Z, Sun J, Chen W, Jin H, Zheng J, Wu Y. Involvement of discoidin domain 1 receptor in recurrence of hepatocellular carcinoma by genome-wide analysis. Med Oncol 2012;29:3077-82. [DOI: 10.1007/s12032-012-0277-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
242 Benedetto ND, Peralta M, Alvarez E, Schroder MT, Estepo C, Paz S, Fainboim H. Incidence of hepatocellular carcinoma in hepatitis C cirrhotic patients with and without HIV infection: a cohort study, 1999-2011. Annals of Hepatology 2014;13:38-44. [DOI: 10.1016/s1665-2681(19)30902-0] [Cited by in Crossref: 8] [Article Influence: 1.0] [Reference Citation Analysis]
243 De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol. 2002;193:59-63. [PMID: 12161002 DOI: 10.1016/s0303-7207(02)00096-5] [Cited by in Crossref: 107] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
244 Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, Rosen M, Soulen M, Shaked A, Reddy KR. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10:911-918. [PMID: 15237377 DOI: 10.1002/lt.20140] [Cited by in Crossref: 158] [Cited by in F6Publishing: 137] [Article Influence: 9.3] [Reference Citation Analysis]
245 Saar B, Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int. 2008;28:189-199. [PMID: 18251978 DOI: 10.1111/j.1478-3231.2007.01655.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
246 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States: NAFLD May Be a Common Underlying Liver Disease in Patients With Hepatocellular Carcinoma in the United States. Hepatology 2002;36:1349-54. [DOI: 10.1002/hep.1840360609] [Cited by in Crossref: 271] [Cited by in F6Publishing: 128] [Article Influence: 18.1] [Reference Citation Analysis]
247 Nair S, Shiv Kumar K, Thuluvath PJ. Mortality from hepatocellular and biliary cancers: changing epidemiological trends. Am J Gastroenterol 2002;97:167-71. [PMID: 11808943 DOI: 10.1111/j.1572-0241.2002.05432.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 0.8] [Reference Citation Analysis]
248 Davis CR. Interventional radiological treatment of hepatocellular carcinoma. Cancer Control 2010;17:87-99. [PMID: 20404792 DOI: 10.1177/107327481001700204] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
249 Deuffic-Burban S, Mohamed MK, Larouze B, Carrat F, Valleron AJ. Expected increase in hepatitis C-related mortality in Egypt due to pre-2000 infections. J Hepatol. 2006;44:455-461. [PMID: 16310281 DOI: 10.1016/j.jhep.2005.08.008] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 3.5] [Reference Citation Analysis]
250 Wong RJ, Devaki P, Nguyen L, Cheung R, Cho–phan C, Nguyen MH. Increased Long-term Survival Among Patients With Hepatocellular Carcinoma After Implementation of Model for End-stage Liver Disease Score. Clinical Gastroenterology and Hepatology 2014;12:1534-1540.e1. [DOI: 10.1016/j.cgh.2013.12.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
251 Wong N, Haydon A, Kemp W, Wijeratne P, Roberts S. Improved survival trend of patients with hepatocellular carcinoma at an Australian tertiary hospital between 1995-2009. Intern Med J 2013;43:197-203. [PMID: 22372378 DOI: 10.1111/j.1445-5994.2012.02755.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
252 Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, Hu RM. Decreased expression of p39 is associated with a poor prognosis in human hepatocellular carcinoma. Med Oncol 2011;28 Suppl 1:S239-45. [PMID: 20936377 DOI: 10.1007/s12032-010-9707-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
253 Lah JJ, Cui W, Hu KQ. Effects and mechanisms of silibinin on human hepatoma cell lines. World J Gastroenterol 2007; 13(40): 5299-5305 [PMID: 17879397 DOI: 10.3748/wjg.v13.i40.5299] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 60] [Article Influence: 4.3] [Reference Citation Analysis]
254 Deuffic-burban S, Mathurin P, Valleron A. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res 2009;18:233-52. [DOI: 10.1177/0962280208094697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
255 Shen D, Zheng J, Cui X, Chen Y, He Q, Lv R, Li Z, Zhao S. Analysis of cholyglycine acid as a biomarker for the early diagnosis of liver disease by fluorescence polarization immunoassay. Sensors and Actuators B: Chemical 2018;256:846-52. [DOI: 10.1016/j.snb.2017.10.013] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
256 Liao R, Zhang D, Li X, Ma J, Yu J, Yang C, Xiong H, Zhou B, Huang X, Tang Z. A Preliminary Study on the Diagnostic Efficacy of Proton Magnetic Resonance Spectroscopy at 3.0T in Rabbit With VX2 Liver Tumor. Technol Cancer Res Treat 2021;20:15330338211036852. [PMID: 34372732 DOI: 10.1177/15330338211036852] [Reference Citation Analysis]
257 Hu KQ. Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med. 2002;139:234-243. [PMID: 12024111 DOI: 10.1067/mlc.2002.122281] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
258 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1002/hep.1840360710] [Cited by in Crossref: 202] [Cited by in F6Publishing: 128] [Article Influence: 10.1] [Reference Citation Analysis]
259 Yao W, Wang K, Jiang Y, Huang Z, Huang Y, Yan H, Huang S, Chen M, Liao J. Serum profile of low molecular weight fucosylated glycoproteins for early diagnosis of hepatocellular carcinoma. Oncol Lett 2020;20:1597-606. [PMID: 32724401 DOI: 10.3892/ol.2020.11727] [Reference Citation Analysis]
260 Kim Y, Stahl CC, Makramalla A, Olowokure OO, Ristagno RL, Dhar VK, Schoech MR, Chadalavada S, Latif T, Kharofa J, Bari K, Shah SA. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250-1258. [PMID: 29033224 DOI: 10.1016/j.surg.2017.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
261 Nguyen QV, Lym JS, Huynh CT, Kim BS, Jae HJ, Kim YI, Lee DS. A novel sulfamethazine-based pH-sensitive copolymer for injectable radiopaque embolic hydrogels with potential application in hepatocellular carcinoma therapy. Polym Chem 2016;7:5805-18. [DOI: 10.1039/c6py01141a] [Cited by in Crossref: 22] [Article Influence: 3.7] [Reference Citation Analysis]